The stock of Neos Therapeutics Inc (NASDAQ:NEOS) reached all time low today, Nov, 3 and still has $4.90 target or 11.00% below today’s $5.50 share price. This indicates more downside for the $86.14 million company. This technical setup was reported by Barchart.com. If the $4.90 PT is reached, the company will be worth $9.48M less.
Trading stocks at an all time low is not easy. Stock at an all time low usually experience even more downside due to very negative fundament. Even thought the pullback rate is high, shorting is not an easy job because the risk of being wrong is big and the risk-reward ratio is always worse than if trading lon only. The stock decreased 4.35% or $0.25 during the last trading session, hitting $5.5. About 75,698 shares traded hands. Neos Therapeutics Inc (NASDAQ:NEOS) has declined 46.46% since April 1, 2016 and is downtrending. It has underperformed by 47.68% the S&P500.
Analysts await Neos Therapeutics Inc (NASDAQ:NEOS) to report earnings on November, 8. They expect $-1.61 EPS, down 159.68% or $0.99 from last year’s $-0.62 per share. After $-1.58 actual EPS reported by Neos Therapeutics Inc for the previous quarter, Wall Street now forecasts 1.90% negative EPS growth.
Neos Therapeutics Inc (NASDAQ:NEOS) Ratings Coverage
Out of 4 analysts covering Neos Therapeutics (NASDAQ:NEOS), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Neos Therapeutics has been the topic of 8 analyst reports since August 17, 2015 according to StockzIntelligence Inc. As per Monday, August 17, the company rating was initiated by JMP Securities. RBC Capital Markets maintained the stock with “Outperform” rating in Thursday, November 12 report. The stock of Neos Therapeutics Inc (NASDAQ:NEOS) has “Outperform” rating given on Wednesday, June 29 by BMO Capital Markets. Wells Fargo initiated the stock with “Outperform” rating in Friday, February 19 report. JMP Securities maintained Neos Therapeutics Inc (NASDAQ:NEOS) on Wednesday, March 9 with “Market Outperform” rating. BMO Capital Markets initiated the shares of NEOS in a report on Monday, August 17 with “Outperform” rating. RBC Capital Markets initiated Neos Therapeutics Inc (NASDAQ:NEOS) on Monday, August 17 with “Outperform” rating.
According to Zacks Investment Research, “Neos Therapeutics, Inc. is engaged in developing, manufacturing and commercializing products for the treatment of attention deficit hyperactivity disorder using drug delivery technologies. Its product candidates include NT-0102 methylphenidate XR orally disintegrating tablet for the treatment of ADHD; NT-0202 amphetamine XR orally disintegrating tablet for the treatment of ADHD; NT-0201 amphetamine XR liquid suspension for the treatment of ADHD and Generic Tussionex, which are in different clinical development stage. Neos Therapeutics, Inc. is headquartered in Grand Prairie, Texas.”
More notable recent Neos Therapeutics Inc (NASDAQ:NEOS) news were published by: Prnewswire.com which released: “SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation …” on September 19, 2016, also Quotes.Wsj.com with their article: “News Neos Therapeutics Inc.NEOS” published on April 22, 2015, Businesswire.com published: “Robbins Arroyo LLP Is Investigating the Officers and Directors of Neos …” on November 01, 2016. More interesting news about Neos Therapeutics Inc (NASDAQ:NEOS) were released by: Globenewswire.com and their article: “Neos Therapeutics Receives Complete Response Letter From the FDA for Cotempla …” published on November 10, 2015 as well as Globenewswire.com‘s news article titled: “Neos Therapeutics Announces Pricing of Initial Public Offering” with publication date: July 23, 2015.
NEOS Company Profile
Neos Therapeutics, Inc., incorporated on June 15, 2009, is a pharmaceutical company. The Firm is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. The Company’s segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. The Firm has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD). The Company’s product candidates are extended-release (XR), medications in patient-friendly, orally disintegrating tablets (ODT) or liquid suspension dosage forms. The Company’s branded product and product candidates incorporate over two of the prescribed medications for the treatment of ADHD, methylphenidate and amphetamine. The Company’s modified-release drug delivery platform has enabled it to create extended-release ODT and liquid suspension dosage forms of the medications.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.